scholarly journals Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST)

2018 ◽  
Author(s):  
Candace Moore ◽  
Alexander Nikolaev
Keyword(s):  
Positron Emission Tomography ◽  
Solid Tumors ◽  
Emission Tomography ◽  
Response Criteria ◽  
Positron Emission

scholarly journals Imaging Assessment of Tumor Response in the Era of Immunotherapy

Diagnostics ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1041
Author(s):  
Jun Nakata ◽  
Kayako Isohashi ◽  
Yoshihiro Oka ◽  
Hiroko Nakajima ◽  
Soyoko Morimoto ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Solid Tumors ◽  
False Positive ◽  
Progressive Disease ◽  
Tumor Response ◽  
Metabolic Response ◽  
Evaluation Criteria ◽  
Emission Tomography ◽  
Response Criteria ◽  
Positron Emission

Assessment of tumor response during treatment is one of the most important purposes of imaging. Before the appearance of immunotherapy, response evaluation criteria in solid tumors (RECIST) and positron emission tomography response criteria in solid tumors (PERCIST) were, respectively, the established morphologic and metabolic response criteria, and cessation of treatment was recommended when progressive disease was detected according to these criteria. However, various types of immunotherapy have been developed over the past 20 years, which show novel false positive findings on images, as well as distinct response patterns from conventional therapies. Antitumor immune response itself causes 18F-fluorodeoxyglucose (FDG) uptake in tumor sites, known as “flare phenomenon”, so that positron emission tomography using FDG can no longer accurately identify remaining tumors. Furthermore, tumors often initially increase, followed by stability or decrease resulting from immunotherapy, which is called “pseudoprogression”, so that progressive disease cannot be confirmed by computed tomography or magnetic resonance imaging at a single time point. As a result, neither RECIST nor PERCIST can accurately predict the response to immunotherapy, and therefore several new response criteria fixed for immunotherapy have been proposed. However, these criteria are still controversial, and also require months for response confirmation. The establishment of optimal response criteria and the development of new imaging technologies other than FDG are therefore urgently needed. In this review, we summarize the false positive images and the revision of response criteria for each immunotherapy, in order to avoid discontinuation of a truly effective immunotherapy.

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

2012 ◽  
Vol 30 (3) ◽  
pp. 282-290 ◽  
Author(s):  
Johanna C. Bendell ◽  
Jordi Rodon ◽  
Howard A. Burris ◽  
Maja de Jonge ◽  
Jaap Verweij ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Emission Tomography ◽  
Class I ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study ◽  
C Peptide ◽  
Positron Emission ◽  
Grade 3

Purpose This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), safety, preliminary activity, pharmacokinetics (PK), and pharmacodynamics of BKM120, a potent and highly specific oral pan-Class I PI3K inhibitor. Patients and Methods Thirty-five patients with advanced solid tumors received daily BKM120 12.5 to 150 mg. Dose escalation was guided by a Bayesian logistic regression model with overdose control. Assessments included archival tumor molecular status, response by Response Evaluation Criteria in Solid Tumors (RECIST), positron emission tomography tracer uptake ([18F]fluorodeoxyglucose positron emission tomography [FDG-PET]), fasting plasma C-peptide, and phosphorylated ribosomal protein S6 (pS6) in skin biopsies. Results Overall, treatment was well tolerated. Dose-limiting toxicities were grade 2 mood alteration (80 mg), grade 3 epigastralgia, grade 3 rash, grade 2 and grade 3 mood alteration (100 mg), and two grade 4 hyperglycemia (150 mg). The MTD was 100 mg/d. Frequent treatment-related adverse events included rash, hyperglycemia, diarrhea, anorexia, and mood alteration (37% each); nausea (31%); fatigue (26%); pruritus (23%); and mucositis (23%). BKM120 demonstrated rapid absorption, half-life of ∼40 hours, ∼three-fold steady-state accumulation, dose-proportional exposure, and moderate interpatient variability. One patient demonstrated a confirmed partial response (triple-negative breast cancer); seven patients (20%) were on study for ≥ 8 months. BKM120 demonstrated dose-dependent pharmacodynamic effects on [18F]FDG-PET, fasting C-peptide, fasting blood glucose, and pS6. No significant trends were seen to correlate tumor molecular alterations with clinical activity. Conclusion This study demonstrates feasibility and proof-of-concept of class I PI3K inhibition in patients with advanced cancers. BKM120, at the MTD of 100 mg/d, is safe and well tolerated, with a favorable PK profile, clear evidence of target inhibition, and preliminary antitumor activity.

Fluorine-18-Labeled Benzamide Analogues for Imaging the σ2Receptor Status of Solid Tumors with Positron Emission Tomography

2007 ◽  
Vol 50 (14) ◽  
pp. 3194-3204 ◽  
Author(s):  
Zhude Tu ◽  
Jinbin Xu ◽  
Lynne A. Jones ◽  
Shihong Li ◽  
Craig Dumstorff ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Solid Tumors ◽  
Emission Tomography ◽  
Positron Emission

scholarly journals Predictive value of positron emission tomography for the prognosis of molecularly targeted therapy in solid tumors

2018 ◽  
Vol Volume 11 ◽  
pp. 8885-8899 ◽  
Author(s):  
Xianhe Xie ◽  
Huijuan Chen ◽  
Haitao Yang ◽  
Heng Lin ◽  
Sijing Zhou ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Targeted Therapy ◽  
Solid Tumors ◽  
Predictive Value ◽  
Emission Tomography ◽  
Molecularly Targeted Therapy ◽  
Positron Emission

scholarly journals Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting

2017 ◽  
Vol 35 (22) ◽  
pp. 2580-2587 ◽  
Author(s):  
Julie R. Park ◽  
Rochelle Bagatell ◽  
Susan L. Cohn ◽  
Andrew D. Pearson ◽  
Judith G. Villablanca ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Bone Marrow ◽  
Clinical Trials ◽  
National Cancer Institute ◽  
Emission Tomography ◽  
Response Criteria ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
Positron Emission ◽  
Planning Meeting ◽  
Fluorodeoxyglucose Positron Emission

Purpose More than two decades ago, an international working group established the International Neuroblastoma Response Criteria (INRC) to assess treatment response in children with neuroblastoma. However, this system requires modification to incorporate modern imaging techniques and new methods for quantifying bone marrow disease that were not previously widely available. The National Cancer Institute sponsored a clinical trials planning meeting in 2012 to update and refine response criteria for patients with neuroblastoma. Methods Multidisciplinary investigators from 13 countries reviewed data from published trials performed through cooperative groups, consortia, and single institutions. Data from both prospective and retrospective trials were used to refine the INRC. Monthly international conference calls were held from 2011 to 2015, and consensus was reached through review by working group leadership and the National Cancer Institute Clinical Trials Planning Meeting leadership council. Results Overall response in the revised INRC will integrate tumor response in the primary tumor, soft tissue and bone metastases, and bone marrow. Primary and metastatic soft tissue sites will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) and iodine-123 (123I) –metaiodobenzylguanidine (MIBG) scans or [18F]fluorodeoxyglucose–positron emission tomography scans if the tumor is MIBG nonavid. 123I-MIBG scans, or [18F]fluorodeoxyglucose–positron emission tomography scans for MIBG-nonavid disease, replace technetium-99m diphosphonate bone scintigraphy for osteomedullary metastasis assessment. Bone marrow will be assessed by histology or immunohistochemistry and cytology or immunocytology. Bone marrow with ≤ 5% tumor involvement will be classified as minimal disease. Urinary catecholamine levels will not be included in response assessment. Overall response will be defined as complete response, partial response, minor response, stable disease, or progressive disease. Conclusion These revised criteria will provide a uniform assessment of disease response, improve the interpretability of clinical trial results, and facilitate collaborative trial designs.

Sign in / Sign up

Export Citation Format

Share Document